Cargando…
Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury
Hepatic ischemia-reperfusion injury (HIRI) is the major complication of liver surgery and liver transplantation, that may increase the postoperative morbidity, mortality, tumor progression, and metastasis. The underlying mechanisms have been extensively investigated in recent years. Among these, oxi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507504/ https://www.ncbi.nlm.nih.gov/pubmed/37731999 http://dx.doi.org/10.3748/wjg.v29.i33.4927 |
_version_ | 1785107332766629888 |
---|---|
author | Shao, Jia-Li Wang, Li-Juan Xiao, Ji Yang, Jin-Feng |
author_facet | Shao, Jia-Li Wang, Li-Juan Xiao, Ji Yang, Jin-Feng |
author_sort | Shao, Jia-Li |
collection | PubMed |
description | Hepatic ischemia-reperfusion injury (HIRI) is the major complication of liver surgery and liver transplantation, that may increase the postoperative morbidity, mortality, tumor progression, and metastasis. The underlying mechanisms have been extensively investigated in recent years. Among these, oxidative stress, inflammatory responses, immunoreactions, and cell death are the most studied. Non-coding RNAs (ncRNAs) are defined as the RNAs that do not encode proteins, but can regulate gene expressions. In recent years, ncRNAs have emerged as research hotspots for various diseases. During the progression of HIRI, ncRNAs are differentially expressed, while these dysregulations of ncRNAs, in turn, have been verified to be related to the above pathological processes involved in HIRI. ncRNAs mainly contain microRNAs, long ncRNAs, and circular RNAs, some of which have been reported as biomarkers for early diagnosis or assessment of liver damage severity, and as therapeutic targets to attenuate HIRI. Here, we briefly summarize the common pathophysiology of HIRI, describe the current knowledge of ncRNAs involved in HIRI in animal and human studies, and discuss the potential of ncRNA-targeted therapeutic strategies. Given the scarcity of clinical trials, there is still a long way to go from pre-clinical to clinical application, and further studies are needed to uncover their potential as therapeutic targets. |
format | Online Article Text |
id | pubmed-10507504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-105075042023-09-20 Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury Shao, Jia-Li Wang, Li-Juan Xiao, Ji Yang, Jin-Feng World J Gastroenterol Review Hepatic ischemia-reperfusion injury (HIRI) is the major complication of liver surgery and liver transplantation, that may increase the postoperative morbidity, mortality, tumor progression, and metastasis. The underlying mechanisms have been extensively investigated in recent years. Among these, oxidative stress, inflammatory responses, immunoreactions, and cell death are the most studied. Non-coding RNAs (ncRNAs) are defined as the RNAs that do not encode proteins, but can regulate gene expressions. In recent years, ncRNAs have emerged as research hotspots for various diseases. During the progression of HIRI, ncRNAs are differentially expressed, while these dysregulations of ncRNAs, in turn, have been verified to be related to the above pathological processes involved in HIRI. ncRNAs mainly contain microRNAs, long ncRNAs, and circular RNAs, some of which have been reported as biomarkers for early diagnosis or assessment of liver damage severity, and as therapeutic targets to attenuate HIRI. Here, we briefly summarize the common pathophysiology of HIRI, describe the current knowledge of ncRNAs involved in HIRI in animal and human studies, and discuss the potential of ncRNA-targeted therapeutic strategies. Given the scarcity of clinical trials, there is still a long way to go from pre-clinical to clinical application, and further studies are needed to uncover their potential as therapeutic targets. Baishideng Publishing Group Inc 2023-09-07 2023-09-07 /pmc/articles/PMC10507504/ /pubmed/37731999 http://dx.doi.org/10.3748/wjg.v29.i33.4927 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Review Shao, Jia-Li Wang, Li-Juan Xiao, Ji Yang, Jin-Feng Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title | Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title_full | Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title_fullStr | Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title_full_unstemmed | Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title_short | Non-coding RNAs: The potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
title_sort | non-coding rnas: the potential biomarker or therapeutic target in hepatic ischemia-reperfusion injury |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507504/ https://www.ncbi.nlm.nih.gov/pubmed/37731999 http://dx.doi.org/10.3748/wjg.v29.i33.4927 |
work_keys_str_mv | AT shaojiali noncodingrnasthepotentialbiomarkerortherapeutictargetinhepaticischemiareperfusioninjury AT wanglijuan noncodingrnasthepotentialbiomarkerortherapeutictargetinhepaticischemiareperfusioninjury AT xiaoji noncodingrnasthepotentialbiomarkerortherapeutictargetinhepaticischemiareperfusioninjury AT yangjinfeng noncodingrnasthepotentialbiomarkerortherapeutictargetinhepaticischemiareperfusioninjury |